Retreatment of Helicobacter pylori infection after initial treatment failure

American Journal of Gastroenterology

Volumn 96, Issue 5, 2001, Pages 1335-1339

  Kearney, David J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; CLARITHROMYCIN; ERYTHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; RANITIDINE; RIFABUTIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; ENDOSCOPY; ESOPHAGUS BIOPSY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; RETREATMENT; REVIEW; TREATMENT FAILURE;

EID: 0035008094     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02351-6     Document Type: Review

References (65)

1. Tytgat G.N.J. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther. 8:1994;359-368.
2. Penston J.G. Helicobacter pylori eradication - Understandable caution but no excuse for inertia. Aliment Pharmacol Ther. 8:1994;369-389.
3. van der Hulst R.W., Keller J.J., Rauws E.A., Tygat G.N. Treatment of Helicobacter pylori infection A review of the world literature . Helicobacter. 1:1996;6-19.
4. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology. 113:1997;S131-S148.
5. Walsh J.H., Peterson W.L. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 333:1995;984-991.
6. Lind T., Veldhuyzen van Zanten S., Unge P., et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials The MACH 1 study . Helicobacter. 1:1996;138-144.
7. Lind T., Megraud F., Unge P., et al. The MACH 2 study Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies . Gastroenterology. 116:1999;248-253.
8. Misiewicz J.J., Harris A.W., Bardham K.D., et al. One week low-dose triple therapy for eradication of H. pylori A large multicentre, randomized trial . Gut. 38:1996;A1.
9. Huang J.Q., Hunt R.H. Treatment after failure The problem of "non-responders." Gut. 45:1999;140-144.
10. Graham D.Y., Lew G.M., Malaty H.M., et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 102:1992;493-496.
11. Wermeille J., Dederding J.P., Cunningham M., et al. Failure of Helicobacter pylori eradication in an ambulatory population Is poor compliance the main cause? Digestion. 59:1998;437.
12. Kearney D.J., Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States Results from 224 patients . Dig Dis Sci. 45:1999;265-271.
13. Osato M.S., Reddy R., Reddy S.G., et al. Reliable determination of metronidazole and clarithromycin susceptibility Comparison of methods and assessment of internal variability using simultaneously obtained antral and corpus biopsies . Gastroenterology. 118:2000;A676.
14. Megraud F., Lehn N., Lind T., et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial The MACH 2 study . Antimicrob Agents Chemother. 43:1999;2747-2752.
15. Realdi G., Dore M.P., Piana A., et al. Pretreatment antibiotic resistance in Helicobacter pylori infection Results of three randomized controlled studies . Helicobacter. 4:1999;106-112.
16. Ling TK, Cheng AF, Sung JJ, et al. An increase in Helicobacter pylori strains resistant to metronidazole: A five-year study [published erratum in Helicobacter 1996;1:129]. Helicobacter 1996;1:57-61.
17. Osato M.S., Reddy R., Graham D.Y. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents. 12:1999;341-347.
18. Meyer J.M., Higgins K.M., Wang W., et al. Evaluation of risk factors in the surveillance of Helicobacter pylori Antimicrobial Resistance Partnership (SHARP) in the United States from 1993-1999. Gastroenterology. 118:2000;A3702.
19. Friedman C.R., Gold B.D., Zirnstein G., et al. H. pylori antimicrobial resistance in the United States. Preliminary results of a 9-center study. Am J Gastroenterol. 118:2000;A3829.
20. Pilotto A., Leandro G., Franceschi M., et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther. 13:1999;667-673.
21. Pieramico O., Zanetti M.V. Role of metronidazole and clarithromycin resistance on the outcome of omeprazole-based triple therapies for H. pylori eradication. Gut. 45:1999;A116.
22. Mégraud F. Resistance of Helicobacter pylori to antibiotics The main limitation of current proton-pump inhibitor triple therapy . Eur J Gastroenterol Hepatol. 11:1999;S35-S37.
23. Bazzoli F., Berretti D., De Luca L., et al. What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? Eur J Gastroenterol Hepatol. 11:1999;S39-S45.
24. Gschwantler M., Dragosics B., Schutze K., et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori - A randomized, controlled trial. Aliment Pharmacol Ther. 13:1999;1063-1069.
25. Midolo P.D., Lambert J.R., Turnidge J. Metronidazole resistance A predictor of failure of Helicobacter pylori eradication by triple therapy . J Gastroenterol Hepatol. 11:1996;290-292.
26. Houben M.H., Van Der Beek D., Hensen E.F., et al. A systematic review of Helicobacter pylori eradication therapy-The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 13:1999;1047-1055.
27. Lerang F., Moum B., Ragnhildstveit E., et al. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection Experience from clinical practice in a population with a high frequency of metronidazole resistance . Am J Gastroenterol. 93:1998;212-216.
28. Houben M.H., Hensen E.F., Rauws E.A., et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. Aliment Pharmacol Therapeut. 13:1999;883-889.
29. Moayyedi P., Ragunathan P.L., Mapstone N., et al. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol. 33:1998;160-163.
30. Adamek R.J., Suerbaum S., Pfaffenbach B., Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - Influence on treatment outcome. Am J Gastroenterol. 93:1998;386-389.
31. Lerang F., Moum B., Haug J.B., et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease Does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol. 92:1997;248-253.
32. Veldhuyzen van Zanten S., Hunt R.H., Cockeram A., et al. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis A randomized, double-blind trial showing the importance of metronidazole resistance . Am J Gastroenterol. 93:1998;5-10.
33. Forbes G.M., Collins B.J., McCullough C.A., et al. Short duration therapy for Helicobacter pylori in Western Australia The impact of metronidazole resistance . Aust N Z J Med. 28:1998;13-17.
34. Thijs J.C., Van Zwet A.A., Thijs W.J., et al. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection The significance of imidazole resistance . Aliment Pharmacol Ther. 11:1997;305-309.
35. Dore M.P., Leandro G., Realdi G., et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy A meta-analytical approach . Dig Dis Sci. 45:2000;68-76.
36. Fennerty M.B. Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. Am J Gastroenterol. 93:1998;2-3. (editorial).
37. Unge P., Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroenterol. 220:(suppl):1996;27-40.
38. Pipkin G.A., Williamson R., Wood J.R. Review article One-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori . Aliment Pharmacol Ther. 12:1998;823-837.
39. Laheij R.J.F., Van Rossum L.G.M., Jansen J.B.M.J., et al. Evaluation of treatment regimens to cure Helicobacter pylori infection-A meta-analysis. Aliment Pharmacol Ther. 13:1999;857-864.
40. Gisbert J.P., Gonzalez L., Calvet X., et al. Helicobacter pylori eradication Proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-A meta-analysis of efficacy . Aliment Pharmacol Ther. 14:2000;1141-1150.
41. Frevel M., Daake H., Janisch H.D., et al. Eradication of Helicobacter pylori with pantoprazole and two antibiotics A comparison of two short-term regimens . Aliment Pharmacol Ther. 14:2000;1151-1157.
42. Lind T., Megraud F., Unge P., et al. The MACH 2 study Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies . Gastroenterology. 116:1999;248-253. [see comments].
43. van der Wouden E.J., Thijs J.C., van Zwet A.A., et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens A meta-analysis . Am J Gastroenterol. 94:1999;1751-1759.
44. Graham D.Y. Antibiotic resistance in Helicobacter pylori Implications for therapy . Gastroenterology. 115:1998;1272-1277.
45. de Boer W.A. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients A personal viewpoint . J Clin Gastroenterol. 22:1996;313-316.
46. Gomollon F., Ducons J.A., Ferrero M., et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy A detailed, prospective analysis of 21 consecutive cases . Helicobacter. 4:1999;222-225.
47. van der Hulst R.W., van der Ende A., Homan A., et al. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut. 42:1998;166-169. [see comments].
48. Van der Wouden E.J., Thijs J.C., Zwet A.A., et al. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther. 13:1999;297-302.
49. Williamson R., Pipkin G.A., Wood J.R. New options in Helicobacter pylori eradication Efficacy, resistance and synergy . Scand J Gastroenterol. 225:(suppl):1998;36-40.
50. van der Wouden E.J., Thijs J.C., van Zwet A.A., et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection A randomized, clinical trial . Am J Gastroenterol. 93:1998;1228-1231.
51. Kung N.N., Sung J.J., Yuen N.W., et al. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy A prospective randomized controlled trial . Am J Gastroenterol. 94:1999;721-724.
52. Lopez-Brea M., Domingo D., Sanchez I., et al. Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates. J Antimicrob Chemother. 42:1998;309-314.
53. Gisbert J.P., Gisbert J.L., Marcos S., et al. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure Omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole . Aliment Pharmacol Ther. 13:1999;1311-1316.
54. Gasbarrini A., Ojetti V., Armuzzi A., et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 14:2000;79-83.
55. Chan F.K., Sung J.J., Suen R., et al. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther. 14:2000;91-95.
56. Rinaldi V., Zullo A., De Francesco V., et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther. 13:1999;163-168.
57. Battaglia G., Di Mario F., Vigneri S., et al. Strategy for the retreatment of failed Helicobacter pylori eradication therapy A case series . Ital J Gastroenterol Hepatol. 30:1998;370-374. [see comments].
58. Gisbert J.P., Boixeda D., Bermejo F., et al. Re-treatment after H. pylori eradication failure. Which therapy is better? Digestion. 59:1998;410.
59. Rinaldi V., Zullo A., Pugliano F., et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 11:1997;929-933.
60. Houben M.H.M.G., van de Beek D., van 't Hoff B.W.M., et al. PPI-triple therapy failure in Helicobacter pylori (Hp) infection. Re-treatment with PPI-triple therapy or quadruple therapy? Digestion. 59:1998;413.
61. Sheu B.S., Wu J.J., Yang S.B., et al. One-week proton pump inhibitor-based triple therapy is effective to eradicate the residual H. pylori after dual therapy. Digestion. 59:1998;430.
62. Ricci C., Menegatti M., Landi F., et al. Failure of eradicating Helicobacter pylori (Hp) treatment. Which is the next step? Digestion. 59:1998;427.
63. Perri F., Festa V., Clemente R., et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther. 14:2000;311-316.
64. Perri F., Festa V., Clemente R., et al. Randomized study on two "rescue" therapies for H. pylori infected patients after failure of standard "triple therapy" regimens. Gastroenterology. 118:2000;A881.
65. Breuer T., Graham D.Y. Costs of diagnosis and treatment of Helicobacter pylori infection When does choosing the treatment regimen based on susceptibility testing become cost effective . Am J Gastroenterol. 94:1999;725-729.